RxDoctor Payments Data

Robert Bucelli, MD

Neurology · Saint Louis, MONPI 1295932960

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $21,513 of the $23,590 with a category attached, or 91.2%. Biogen accounts for 62.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $8,193 and has fallen 86.7% since, to $1,089 in 2025.

$23,590in general payments, 2019–2025

Across 26 payments — averaging $907.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$15K
  • Regeneron$8K
  • Sarepta Therapeutics, Inc.$1K
  • Pfizer$28
$8,506,320in research payments, 2019–2025

Across 36 payments — averaging $236,287 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$8.5M

What the payments were for

  • Consulting fees$21,51391%
  • Speaking & faculty fees$4072%
  • Travel & lodging$1,3376%
  • Food & beverage$3331%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen7$14,849
Regeneron12$7,639
Sarepta Therapeutics, Inc.5$1,073
Pfizer2$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,590 in reported general payments places this provider in the 85th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$53,930
Medicare patients
187
Services billed
553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5026$385,770
Radicava OrsEdaravone17$235,563
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5011$169,614
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5022$125,459
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$75,212
NuedextaDextromethorphan Hbr/Quinidine18$32,204
Carbamazepine ErCarbamazepine20$1,517
Duloxetine Hcl37$1,439
Pregabalin55$977
Gabapentin54$940
Baclofen18$492
MethotrexateMethotrexate Sodium11$205
Prednisone37$118
Venlafaxine Hcl ErVenlafaxine Hcl11$115
Clonazepam13$35

Paid to pharmacies, not to this prescriber.

Other neurology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →